View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/26/2018 9:05:20 AM 1397

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Trial Results of Progenza for Knee Osteoarthritis Published

🕔3/7/2018 10:55:47 AM 2875

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.

Read Full Article

Regeneus Ltd (ASX:RGS) 2018 Half-Year Results and Business Update

🕔2/20/2018 1:43:32 PM 2083

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Half-Year Report for the 6 months to 31 December 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Progenza Granted Advanced Therapy Medicinal Product Designation by European Medicines Agency

🕔2/14/2018 9:42:32 AM 2685

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Progenza has been granted an Advanced Therapy Medicinal Product classification by the Committee for Advanced Therapies of the European Medicines Agency, following consultation with the European Commission.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Patent Office to Grant Patent for Cancer Vaccine Technology

🕔2/12/2018 9:48:27 AM 3666

Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.

Read Full Article

Regeneus Ltd (ASX:RGS) Announces Successful Results in Acne Study

🕔2/6/2018 10:45:05 AM 2969

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.

Read Full Article

Regeneus Ltd (ASX:RGS) Appoints Japan-Based Non-Executive Director with Extensive Pharmaceutical Industry Experience

🕔12/11/2017 9:59:39 AM 2220

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO Presentation

🕔11/2/2017 12:58:57 PM 3073

Regeneus Ltd (ASX:RGS) provides the Company's Chairman's address to shareholders and CEO presentation at 2017 Annual General Meeting.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation on Japan First Strategy at Ord Minnett

🕔11/1/2017 12:41:09 PM 2526

Regeneus Ltd (ASX:RGS) provides the Company's Presentation on Japan First Strategy at Ord Minnett.

Read Full Article

Regeneus Ltd (ASX:RGS) Sygenus Shows Longer Lasting Effect on Pain than Morphine

🕔9/26/2017 9:29:00 AM 2971

Regeneus Ltd (ASX:RGS) , a clinical-stage regenerative medicine company, today announced that a preclinical post-operative pain study has shown that topical application of Sygenus, has significantly greater and longer lasting analgesic effect than an injection of morphine.

Read Full Article
###

85,261 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 173) (Last 30 Days: 840) (Since Published: 39771) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media